Fed. Circ. Asks What's New About Schizophrenia Drug Patent
The Federal Circuit spent a chunk of the morning Friday trying to nail down exactly what wasn't obvious about a schizophrenia drug patent held by Janssen that Teva Pharmaceuticals failed to...To view the full article, register now.
Already a subscriber? Click here to view full article